A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.

Also called NCT04712669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 108 participants (enrolled count) (from the registry)
Sponsor
Altavant Sciences GmbH (from the registry)
Registry
  • NCT NCT04712669
Other papers using this trial's data
  • Rodatristat ethyl decreases activity in pulmonary arterial hypertension: results from the ELEVATE-2 trial Annals of the American Thoracic Society, 2026-05-01 DOI, PubMed 41973984, PMC13152660 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial The Lancet. Respiratory medicine, 2024-11 DOI, PubMed 39307144

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Bosnia & Herzegovina, Bulgaria, Canada, Czechia, France, Germany, Italy, Latvia, Moldova, Poland, Serbia, Spain, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04712669. Randomized; quadruple masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2023-06-05 (actual). Results posted on 2025-06-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
rodatristat ethyl 300 mg tablet BID
Intervention (Drug)
rodatristat ethyl 600 mg BID
Intervention (Drug)
Placebo
Lead sponsor
Altavant Sciences GmbH (class: industry)

Record details

Record id
cardio:ct-nct04712669
Content hash
e0048fabfed4d6ad94673c75345ddba103bf9dd2cdbba0ab5cac77dd07e8615b